Clinical trials: Plasma Cell Tumor
Multiple Myeloma, Hypogammaglobulinemia
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
- Conditions
- Multiple Myeloma, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired
- Trial name
- NCT06976476
- Testing
- IgPro20
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00053989
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Myeloma
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a…
- Trial name
- NCT02332850
- Testing
- Isatuximab, Carfilzomib, Dexamethasone
- Where
- 6 sites in United States, Canada
- Volunteers
- 83 people
- Sponsor
- Thomas Martin, MD
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
This phase I trial tests the safety, side effects and best dose of MUC1-activated T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory) and is positive for…
- Trial name
- NCT05411497
- Testing
- Autologous MUC1-activated T-cells, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).
- Trial name
- NCT07490613
- Testing
- SHR-3836 administered as multiple doses.
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Multiple Myeloma
A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency.
- Trial name
- NCT02833610
- Testing
- Denosumab Q4W
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma, Blood Stem Cell Transplant Failure
Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies
This is a retrospective observational cohort database analysis. The study will review retrospectively the records of patients undergoing a first peripheral blood stem cell mobilization for multiple myeloma in the databases from…
- Trial name
- MOZOBIL (NCT02997813)
- Where
- 9 sites in France
- Volunteers
- 112 people
- Sponsor
- Intergroupe Francophone du Myelome
Progression Free Survival, Overall Survival
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR (very good PR)after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment.
- Conditions
- Progression Free Survival, Overall Survival, Maintenance
- Trial name
- NCT05477797
- Testing
- Ixazomib DX/Lenalidomide DX
- Where
- China
- Volunteers
- 420 people
- Sponsor
- RenJi Hospital
Hematological Malignancy, Leukemia
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for fever in neutropenic patients.
- Conditions
- Hematological Malignancy, Leukemia, Myelodysplasia, Lymphoma
- Trial name
- NCT00195533
- Testing
- piperacillin-tazobactam, glycopeptide
- Where
- 12 sites in Spain
- Volunteers
- 801 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Multiple Myeloma
Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma
In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been used since the 1960s and is regarded as the standard of care in elderly patients.
- Trial name
- NCT00367185
- Testing
- Thalidomide
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Lille
Multiple Myeloma
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide…
- Trial name
- MonumenTAL-6 (NCT06208150)
- Testing
- Talquetamab, Pomalidomide, Teclistamab
- Where
- 242 sites in United States, Argentina and 25 more
- Volunteers
- 838 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
This phase II MATCH treatment trial identifies the effects of trametinib in patients whose cancer has a has a genetic change called NF1 mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439318
- Testing
- Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance
Bortezomib and cyclophosphamide in combination with dexamethasone has already demonstrated high response rates in refractory multiple myeloma.
- Trial name
- REMM (NCT02467010)
- Testing
- Bortezomib, Cyclophosphamide, Dexamethasone
- Where
- Netherlands
- Volunteers
- 73 people
- Sponsor
- University Medical Center Groningen
Multiple Myeloma, Primary Plasma Cell Leukemia
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.
- Trial name
- NCT06333509
- Testing
- CT071
- Volunteers
- 166 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma, Carfilzomib
The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients
This study is a prospective, single center, single arm phase II clinical trial. The study population consists of patients who have received treatment with VRd or VRd lite regimens for 2-8 courses in the past and have achieved…
- Conditions
- Multiple Myeloma, Carfilzomib, Daratumumab, Pomalidomide
- Trial name
- DKPD (NCT07015021)
- Testing
- Daratumumab, Cafizomide, Pomalidomide
- Volunteers
- 72 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Refractory Multiple Myeloma
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
Phase 2, single-arm, open, non-randomized, multicenter study of the SINE™ compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab.
- Trial name
- NCT03589222
- Testing
- Selinexor, Daratumumab, Bortezomib
- Where
- 15 sites in Spain
- Volunteers
- 62 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
The purpose of this study is to evaluate the effectiveness of Bortezomib when added to standard chemotherapy medicine(s) for treatment of Multiple Myeloma.
- Trial name
- NCT00948922
- Testing
- Bortezomib, Melphalan, Autologous Stem Cell Transplant
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
This study will test the safety of the study treatment, MCARH109, at different doses, to see which dose is safest in people, and to look for any good and bad effects of this treatment.
- Trial name
- NCT04555551
- Testing
- Infusion of MCARH109 T cells
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01432353
- Testing
- DFRF4539A
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.